Last updated: 2026-09-06 00:56:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
DBV Technologies S.A. (DBVT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $13.47, with a market capitalisation of $855.33M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.70 to $26.19. This page covers its latest market performance, valuation, price trends and company information.
$855.33M | |
$13.42 | |
$505.70 | |
$2.20 | |
$13.70 | |
40.24K | |
-- | |
-- | |
$26.19 | |
$8.70 | |
-- | |
-- |
DBV Technologies S.A. (DBVT) last closed at $13.70 as of 2026-09-04 20:35:00, unchanged from the previous close of $13.70.
During the latest regular trading session, DBVT traded between $2.20 and $505.70, with a volume of 40.24K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, DBV Technologies S.A. (DBVT) moved from $13.75 to $13.47, representing a decline of 2.03% ($0.28).
The stock traded between $13.33 and $13.74 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 154.42 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 27.3%
DBVT is currently trading at $13.47, placing it 27.3% of the way from its 52-week low of $8.70 to its 52-week high of $26.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 170 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of DBV Technologies S.A. (DBVT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.